Erythropoietin for neuroprotection in neonatal encephalopathy: Safety and pharmacokinetics

Pediatrics

Volumn 130, Issue 4, 2012, Pages 683-691

  Wu, Yvonne W ^a   Bauer, Larry A ^c   Ballard, Roberta A ^a   Ferriero, Donna M ^a   Glidden, David V ^a   Mayock, Dennis E ^b   Chang, Taeun ^d   Durand, David J ^e   Song, Dongli ^f   Bonifacio, Sonia L ^a   Gonzalez, Fernando F ^a   Glass, Hannah C ^a   Juul, Sandra E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Asphyxia; Hypoxia ischemia; Neonatal encephalopathy; Neuroprotection

Indexed keywords

ERYTHROPOIETIN;

ACIDOSIS; ADULT; APGAR SCORE; AREA UNDER THE CURVE; ARTICLE; BLOOD PH; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HYPOTHERMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MALE; MULTICENTER STUDY; NEUROPROTECTION; NEWBORN; OCCLUSIVE CEREBROVASCULAR DISEASE; PHASE 1 CLINICAL TRIAL; PREMATURITY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESUSCITATION; UNSPECIFIED SIDE EFFECT;

ANALYSIS OF VARIANCE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HALF-LIFE; HUMANS; HYPOTHERMIA, INDUCED; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NEUROPROTECTIVE AGENTS;

EID: 84867170513     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0498     Document Type: Article

References (64)

1. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86(6):329-338
2. Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol. 2008;199(6):587-595
3. Black RE, Cousens S, Johnson HL, et al Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-1987
4. Shankaran S, Laptook AR, Ehrenkranz RA, et al National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574-1584 (Pubitemid 41434636)
5. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663-670 (Pubitemid 40260887)
6. Jacobs SE, Morley CJ, Inder TE, et al Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and nearterm newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. Arch Pediatr Adolesc Med. 2011;165(8):692-700
7. Simbruner G, Mittal RA, Rohlmann F, Muche R; neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. Pediatrics. 2010;126(4). Available at: www.pediatrics.org/cgi/content/full/126/4/e771
8. Azzopardi DV, Strohm B, Edwards AD, et al TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349-1358
9. Shah PS. Hypothermia: a systematic review and meta-analysis of clinical trials. Semin Fetal Neonatal Med . 2010;15(5):238-246
10. Higgins RD, Raju T, Edwards AD, et al. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr. 2011;159(5):851-858.e1
11. Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010;340:c363
12. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke . 2007;38(10):2795-2803 (Pubitemid 47494020)
13. Yang Z, Covey MV, Bitel CL, Ni L, Jonakait GM, Levison SW. Sustained neocortical neurogenesis after neonatal hypoxic/ischemic injury. Ann Neurol . 2007;61(3):199-208 (Pubitemid 46557344)
14. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl. 2002;91(438):36-42 (Pubitemid 35347060)
15. Juul SE, McPherson RJ, Bammler TK, Wilkerson J, Beyer RP, Farin FM. Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model. Dev Neurosci. 2008;30(4):231-242 (Pubitemid 351653366)
16. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004;31(1):129-142 (Pubitemid 38748597)
17. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res. 2005;58(2):297-301 (Pubitemid 41099877)
18. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate. 2001;79(3-4):228-235 (Pubitemid 32247092)
19. Reitmeir R, Kilic E, Kilic U, et al. Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity. Brain. 2011;134(pt 1):84-99
20. McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology. 2007;91(1):36-43 (Pubitemid 46141198)
21. Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res. 2005;57(4):481-487 (Pubitemid 40389334)
22. Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res. 2005;58(1):106-111 (Pubitemid 40967438)
23. Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci . 2007;29(4-5):321-330 (Pubitemid 47343686)
24. Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke. 2010;41(5):1032-1037
25. Kumral A, Uysal N, Tugyan K, et al. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav Brain Res. 2004;153(1):77-86 (Pubitemid 38829291)
26. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in braininjured neonatal rats. Pediatr Res. 2007;61(4):451-455 (Pubitemid 46569299)
27. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, Ferriero DM. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci. 2009;31(5):403-411
28. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2). Available at: www.pediatrics.org/cgi/content/full/124/2/e218
29. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010;125 (5). Available at: www.pediatrics.org/cgi/content/full/125/ 5/e1135
30. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976;33(10):696-705
31. Widness JA, Schmidt RL, Hohl RJ, et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 2007;81(6):873-879 (Pubitemid 46788298)
32. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol. 1996;80(1):140-148 (Pubitemid 26034856)
33. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res. 2007;61(6):671-675 (Pubitemid 46800274)
34. Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci. 1982;71(3):372-373 (Pubitemid 12083746)
35. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979;68(8):1071-1074 (Pubitemid 10099391)
36. Zubrow AB, Hulman S, Kushner H, Falkner B; Philadelphia Neonatal Blood Pressure Study Group. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. J Perinatol. 1995;15(6):470-479
37. Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol. 2000;14(4):332-341 (Pubitemid 30166719)
38. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves crosstalk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412(6847):641-647 (Pubitemid 32772276)
39. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol. 2003;138(6):1107-1118 (Pubitemid 36459833)
40. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased infl ammatory mediators after erythropoietin administration. Stroke. 2005;36(8):1672-1678 (Pubitemid 41098760)
41. Juul SE, Beyer RP, Bammler TK, McPherson RJ, Wilkerson J, Farin FM. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res. 2009;65(5):485-492
42. Zacharias R, Schmidt M, Kny J, et al. Dose-dependent effects of erythropoietin in propofol anesthetized neonatal rats. Brain Res. 2010;1343:14-19
43. Kumral A, Gonenc S, Acikgoz O, et al. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate. 2005;87(1):15-18 (Pubitemid 40091371)
44. Dzietko M, Felderhoff-Mueser U, Sifringer M, et al. Erythropoietin protects the developing brain against N-methyl-Daspartate receptor antagonist neurotoxicity. Neurobiol Dis. 2004;15(2):177-187 (Pubitemid 38296748)
45. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35(7):1732-1737 (Pubitemid 38823656)
46. Ransome MI, Turnley AM. Systemically delivered Erythropoietin transiently enhances adult hippocampal neurogenesis. J Neurochem. 2007;102(6):1953-1965 (Pubitemid 47329277)
47. Böcker-Meffert S, Rosenstiel P, Röhl C, et al. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci. 2002;43(6):2021-2026 (Pubitemid 34587056)
48. Wang L, Chopp M, Gregg SR, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J Cereb Blood Flow Metab. 2008;28(7):1361-1368 (Pubitemid 351896653)
49. Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab. 2002;22(4):393-403 (Pubitemid 34273595)
50. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19(6):643-651 (Pubitemid 30161216)
51. Mu D, Chang YS, Vexler ZS, Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol. 2005;195(2):407-415 (Pubitemid 41297792)
52. Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res. 1999;46(5):543-547 (Pubitemid 29496482)
53. Juul SE, Harcum J, Li Y, Christensen RD. Erythropoietin is present in the cerebrospinal fl uid of neonates. J Pediatr. 1997;130(3):428-430 (Pubitemid 27492688)
54. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004;85(2):138-144 (Pubitemid 38437682)
55. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97(19):10526-10531
56. Plateel M, Teissier E, Cecchelli R. Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. J Neurochem . 1997;68(2):874-877 (Pubitemid 27044754)
57. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol. 2005;61(3):189-195 (Pubitemid 40768551)
58. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics . 2008;122(2):383-391
59. Fauchère JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122(2):375-382
60. McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr. 2010;22(2):139-145
61. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;3(3):CD004863
62. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther. 2010;333(2):528-532
63. Brown MS, Jones MA, Ohls RK, Christensen RD. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J Pediatr. 1993;122(4):655-657 (Pubitemid 23093603)
64. Weber A, Dzietko M, Berns M, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis. 2005;20(2):594-600 (Pubitemid 41476285)